Complete Regression of Choroidal Metastasis Secondary to Non-Small-Cell Lung Cancer with Intravitreal Bevacizumab and Oral Erlotinib Combination Therapy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Seong-Woo | - |
dc.contributor.author | Kim, Myung Jin | - |
dc.contributor.author | Huh, Kuhl | - |
dc.contributor.author | Oh, Jaeryung | - |
dc.date.accessioned | 2021-09-09T01:20:41Z | - |
dc.date.available | 2021-09-09T01:20:41Z | - |
dc.date.created | 2021-06-10 | - |
dc.date.issued | 2009 | - |
dc.identifier.issn | 0030-3755 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/122178 | - |
dc.description.abstract | Purpose: To report a case of a complete regression of choroidal metastasis secondary to non-small-cell lung cancer (NSCLC). Methods: Retrospective case review of a female patient treated with intravitreal bevacizumab and oral erlotinib combination therapy for choroidal metastases secondary to NSCLC. Best corrected visual acuity (BCVA), fluorescein angiography ( FA), optical coherence tomography (OCT), and B-scan ultrasonography were compared during the 4-month treatment period. Results: Four weeks after the third injection of bevacizumab (2.5 mg), the BCVA had improved to 20/40 from 20/200 and the 2 subretinal masses had completely disappeared. FA demonstrated only a retinal pigment epithelial (RPE) window defect with minimal to no leakage. In the B-scan ultrasonography and OCT, no further mass-like lesion was detected. The retina and RPE layer were flattened. Conclusion: Combining intravitreal bevacizumab and oral erlotinib could be another treatment option for patients with choroidal metastasis of NSCLC. Copyright (c) 2009 S. Karger AG, Basel | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | KARGER | - |
dc.subject | ENDOTHELIAL GROWTH-FACTOR | - |
dc.subject | TYROSINE KINASE INHIBITOR | - |
dc.subject | CARCINOMA | - |
dc.title | Complete Regression of Choroidal Metastasis Secondary to Non-Small-Cell Lung Cancer with Intravitreal Bevacizumab and Oral Erlotinib Combination Therapy | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Seong-Woo | - |
dc.contributor.affiliatedAuthor | Huh, Kuhl | - |
dc.contributor.affiliatedAuthor | Oh, Jaeryung | - |
dc.identifier.doi | 10.1159/000229307 | - |
dc.identifier.scopusid | 2-s2.0-67651006008 | - |
dc.identifier.wosid | 000271354000011 | - |
dc.identifier.bibliographicCitation | OPHTHALMOLOGICA, v.223, no.6, pp.411 - 413 | - |
dc.relation.isPartOf | OPHTHALMOLOGICA | - |
dc.citation.title | OPHTHALMOLOGICA | - |
dc.citation.volume | 223 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 411 | - |
dc.citation.endPage | 413 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Ophthalmology | - |
dc.relation.journalWebOfScienceCategory | Ophthalmology | - |
dc.subject.keywordPlus | ENDOTHELIAL GROWTH-FACTOR | - |
dc.subject.keywordPlus | TYROSINE KINASE INHIBITOR | - |
dc.subject.keywordPlus | CARCINOMA | - |
dc.subject.keywordAuthor | Choroidal metastasis | - |
dc.subject.keywordAuthor | Non-small-cell lung cancer | - |
dc.subject.keywordAuthor | Bevacizumab | - |
dc.subject.keywordAuthor | Erlotinib | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.